ReviewJournal of Korean Neurosurgical Society2015
Moyamoya Biomarkers.
Review in Journal of Korean Neurosurgical Society, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Nit2/ω-amidase as a potential non-invasive diagnostic marker for moyamoya disease.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2026Article
- Increased plasma fibronectin mirrors intimal phenotypic switching of vascular smooth muscle cells in moyamoya arteriopathy.Scientific reports · 2025Article
- Lectin-type oxidized LDL receptor-1 as a potential therapeutic target for cerebral cavernous malformations treatment.Frontiers in neuroscience · 2024Article
- Disease specific urinary biomarkers in the central nervous system.Scientific reports · 2023Article
- Review
- An Uncommon Case of Moyamoya Syndrome Is Accompanied by an Arteriovenous Malformation with the Involvement of Dural Arteries.International journal of molecular sciences · 2023Article
- Physiological and pathophysiological mechanisms of the molecular and cellular biology of angiogenesis and inflammation in moyamoya angiopathy and related vascular diseases.Frontiers in neurology · 2023Review
- Bioinformatics analysis reveals the landscape of immune cell infiltration and novel immune-related biomarkers in moyamoya disease.Frontiers in genetics · 2023Article
- Structural abnormalities in paediatric moyamoya disease revealed by clinical magnetic resonance imaging, regionally distributed relative signal intensities and volumes.International journal of developmental neuroscience : the official journal of the International Society for Developmental Neuroscience · 2022Article
- Recurrent transient ischemic attacks in a moyamoya syndrome patient with ultra-long imaging follow-up.Quantitative imaging in medicine and surgery · 2022Article
- RNF213 gene silencing upregulates transforming growth factor β1 expression in bone marrow-derived mesenchymal stem cells and is involved in the onset of Moyamoya disease.Experimental and therapeutic medicine · 2021Article
- Moyamoya as a Cause of Altered Mental Status in the Emergency Department: A Case Report.Clinical practice and cases in emergency medicine · 2021Article
- Pathophysiology of Vascular Stenosis and Remodeling in Moyamoya Disease.Frontiers in neurology · 2021Review
- Non-invasive Urinary Biomarkers in Moyamoya Disease.Frontiers in neurology · 2021Article
- Genetic and Proteomic Contributions to the Pathophysiology of Moyamoya Angiopathy and Related Vascular Diseases.The application of clinical genetics · 2021Review
- Moyamoya disease in a Moroccan baby: a case report.Journal of medical case reports · 2018Article
- Article
- A Recent Update of Clinical and Research Topics Concerning Adult Moyamoya Disease.Journal of Korean Neurosurgical Society · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Moyamoya disease (MMD) is an arteriopathy of the intracranial circulation predominantly affecting the branches of the internal carotid arteries. Heterogeneity in presentation, progression and response to therapy has prompted intense study to improve the diagnosis and prognosis of this disease. Recent progress in the development of moyamoya-related biomarkers has stimulated marked interest in this field. Biomarkers can be defined as biologically derived agents-such as specific molecules or unique patterns on imaging-that can identify the presence of disease or help to predict its course. This article reviews the current categories of biomarkers relevant to MMD-including proteins, cells and genes-along with potential limitations and applications for their use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.